Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
26 pending office actions • 20 art units • 25 examiners • 0 of 26 (0%) have an AI response strategy ready • 23 patents granted in the last 365 days
The United States Of America AS Represented By The Secretary Department Of Health And Human SE has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This 1 action is assigned to 1 distinct examiner and is located in 1 distinct art unit. This indicates a very specific technical focus for the current patent application within the Biotechnology & Pharmaceuticals sector.
FONTAINHAS, AURORA M is the busiest examiner, handling 1 pending office action. This 1 action represents the total 1 pending office actions for the portfolio. Because there is only 1 distinct examiner and 1 distinct art unit, the 1 pending action is being reviewed by a single official. This matching count between the 1 distinct examiner and the total actions highlights the centralized nature of the current prosecution.
Based on the USPTO statutory response window for each pending office action. 9 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 9 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 2 (8%) |
| §103 only | 6 (23%) |
| §102 only | 1 (4%) |
| §112 only | 2 (8%) |
| Double-patenting + other | 8 (31%) |
| Multi-statute (no §101) | 6 (23%) |
| No statute on record | 1 (4%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SANG, HONG | 2 | 55.0% | +62.4% |
| AULAKH, CHARANJIT | 1 | 80.6% | -14.5% |
| MONTGOMERY, ANN Y | 1 | 69.0% | +27.7% |
| BURKHART, MICHAEL D | 1 | 62.3% | +11.7% |
| JOHNSON, ALLISON MARIE | 1 | 40.9% | +53.3% |
| TRAN, CHRISTINA L | 1 | 51.6% | +48.2% |
| LANDSMAN, ROBERT S | 1 | 81.3% | +13.0% |
| HADDAD, MAHER M | 1 | 50.4% | +53.9% |
| VARADARAJ, ARCHANA | 1 | 80.0% | +33.3% |
| REILLY, SOPHIA JANE | 1 | 60.8% | +49.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18812693 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF | AULAKH, CHARANJIT | — |
| 18277220 | Self-Assembling Nanoparticles Based On Amphiphilic Peptides | VARADARAJ, ARCHANA | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18722188 | METHODS AND SYSTEMS FOR ANALYZING TARGET ENGAGEMENT DATA FROM BIOLOGICAL ASSAYS | MONTGOMERY, ANN Y | 30d overdue |
| 18020843 | REAL-TIME CELLULAR THERMAL SHIFT ASSAY (RT-CETSA) FOR RESEARCH AND DRUG DISCOVERY | TSAY, MARSHA M | 26d overdue |
| 17910911 | SYSTEMS, METHODS, AND DEVICES FOR EX VIVO ANALYSIS OF RESECTED TISSUE SAMPLES | HOBBS, MICHAEL L | 6d |
| 18271583 | EXOSOMES COMPRISING IL-35 OR IL-27 AND USES THEREOF | WEBB, WALTER E | 76d |
| 18282919 | BICISTRONIC CHIMERIC ANTIGEN RECEPTORS DESIGNED TO REDUCE RETROVIRAL RECOMBINATION AND USES THEREOF | LANDSMAN, ROBERT S | — |
| 18028463 | PLK1 POLO BOX DOMAIN INHIBITORS AND METHOD OF TREATING CANCER | HERNANDEZ, JACKSON J | — |
| 18020823 | PREFERENTIAL GENERATION OF iPSC CARRYING ANTIGEN SPECIFIC TCRs FROM TUMOR INFILTRATING LYMPHOCYTES | TAKENAKA, RISA | — |
| 17620248 | INTERLEUKIN-27 PRODUCING B-CELLS AND USES THEREOF | THUESON, HANNA MARIE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18722188 | METHODS AND SYSTEMS FOR ANALYZING TARGET ENGAGEMENT DATA FROM BIOLOGICAL ASSAYS | MONTGOMERY, ANN Y | 30d overdue |
| 18220090 | INHIBITORS OF THE PLASMODIAL SURFACE ANION CHANNEL AS ANTIMALARIALS | REILLY, SOPHIA JANE | 6d |
| 18644724 | BICISTRONIC CHIMERIC ANTIGEN RECEPTORS AND THEIR USES | BURKHART, MICHAEL D | — |
| 18623529 | METHODS OF PREPARING AN ISOLATED POPULATION OF DENDRITIC CELLS AND METHODS OF TREATING CANCER USING SAME | JOHNSON, ALLISON MARIE | — |
| 18294048 | AQP1 GENE THERAPY TO PREVENT RADIATION INDUCED SALIVARY HYPOFUNCTION | TRAN, CHRISTINA L | — |
| 18503107 | M971 CHIMERIC ANTIGEN RECEPTORS | SANG, HONG | — |
| 18502993 | M971 CHIMERIC ANTIGEN RECEPTORS | SANG, HONG | — |
| 18282919 | BICISTRONIC CHIMERIC ANTIGEN RECEPTORS DESIGNED TO REDUCE RETROVIRAL RECOMBINATION AND USES THEREOF | LANDSMAN, ROBERT S | — |
| Art Unit | Apps |
|---|---|
| 1647 | 2 |
| 1627 | 2 |
| 1638 | 2 |
| 1678 | 1 |
| 1671 | 1 |
| 1646 | 1 |
| 1641 | 1 |
| 1658 | 1 |
| 1612 | 1 |
| 1651 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18812693 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF | AULAKH, CHARANJIT | — | §103DP | Non-Final OA | — | Pending | Aug 22, 2024 |
| 18722188 | METHODS AND SYSTEMS FOR ANALYZING TARGET ENGAGEMENT DATA FROM BIOLOGICAL ASSAYS | MONTGOMERY, ANN Y | 1678 | §101 | Final Rejection | 30d overdue | Pending | Jun 20, 2024 |
| 18644724 | BICISTRONIC CHIMERIC ANTIGEN RECEPTORS AND THEIR USES | BURKHART, MICHAEL D | — | §102§103§112DP | Non-Final OA | — | Pending | Apr 24, 2024 |
| 18623529 | METHODS OF PREPARING AN ISOLATED POPULATION OF DENDRITIC CELLS AND METHODS OF TREATING CANCER USING SAME | JOHNSON, ALLISON MARIE | 1647 | §102§103§112DP | Non-Final OA | — | Pending | Apr 01, 2024 |
| 18294048 | AQP1 GENE THERAPY TO PREVENT RADIATION INDUCED SALIVARY HYPOFUNCTION | TRAN, CHRISTINA L | 1671 | §103 | Non-Final OA | — | Pending | Jan 31, 2024 |
| 18503107 | M971 CHIMERIC ANTIGEN RECEPTORS | SANG, HONG | — | §112DP | Non-Final OA | — | Pending | Nov 06, 2023 |
| 18502993 | M971 CHIMERIC ANTIGEN RECEPTORS | SANG, HONG | 1646 | §112DP | Non-Final OA | — | Pending | Nov 06, 2023 |
| 18282919 | BICISTRONIC CHIMERIC ANTIGEN RECEPTORS DESIGNED TO REDUCE RETROVIRAL RECOMBINATION AND USES THEREOF | LANDSMAN, ROBERT S | 1647 | §103§112 | Non-Final OA | — | Pending | Sep 19, 2023 |
| 18277521 | HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST CD22 | HADDAD, MAHER M | 1641 | §112 | Non-Final OA | — | Pending | Aug 16, 2023 |
| 18277220 | Self-Assembling Nanoparticles Based On Amphiphilic Peptides | VARADARAJ, ARCHANA | 1658 | §103§112DP | Non-Final OA | — | Pending | Aug 14, 2023 |
| 18220090 | INHIBITORS OF THE PLASMODIAL SURFACE ANION CHANNEL AS ANTIMALARIALS | REILLY, SOPHIA JANE | 1627 | Other | Non-Final OA | 6d | Pending | Jul 10, 2023 |
| 18271583 | EXOSOMES COMPRISING IL-35 OR IL-27 AND USES THEREOF | WEBB, WALTER E | 1612 | §102§103 | Final Rejection | 76d | Pending | Jul 10, 2023 |
| 18028463 | PLK1 POLO BOX DOMAIN INHIBITORS AND METHOD OF TREATING CANCER | HERNANDEZ, JACKSON J | 1627 | §102§103§112 | Final Rejection | — | Pending | Mar 24, 2023 |
| 18026421 | NOVEL ADENO-ASSOCIATED VIRAL (AAV) VECTORS TO TREAT HEREDITARY METHYLMALONIC ACIDEMIA (MMA) CAUSED BY METHYLMALONYL-COA MUTASE (MMUT) DEFICIENCY | ARMATO JR, DENNIS IGNATIUS | 1651 | §102§103DP | Final Rejection | — | Pending | Mar 15, 2023 |
| 17910911 | SYSTEMS, METHODS, AND DEVICES FOR EX VIVO ANALYSIS OF RESECTED TISSUE SAMPLES | HOBBS, MICHAEL L | 1799 | §102§103 | Non-Final OA | 6d | Pending | Feb 15, 2023 |
| 18020823 | PREFERENTIAL GENERATION OF iPSC CARRYING ANTIGEN SPECIFIC TCRs FROM TUMOR INFILTRATING LYMPHOCYTES | TAKENAKA, RISA | 1632 | §103§112 | Non-Final OA | — | Pending | Feb 10, 2023 |
| 18020843 | REAL-TIME CELLULAR THERMAL SHIFT ASSAY (RT-CETSA) FOR RESEARCH AND DRUG DISCOVERY | TSAY, MARSHA M | 1656 | §103§112 | Non-Final OA | 26d overdue | Pending | Feb 10, 2023 |
| 18093902 | METHODS OF PRODUCING ENRICHED POPULATIONS OF TUMOR-REACTIVE T CELLS FROM TUMOR | POPA, ILEANA | 1633 | §103 | Non-Final OA | — | Pending | Jan 06, 2023 |
| 17924784 | RSV VACCINE BEARING ONE OR MORE P GENE MUTATIONS | KINSEY WHITE, NICOLE ERIN | 1672 | §102 | Final Rejection | 78d overdue | Pending | Nov 11, 2022 |
| 17918725 | THYCLOTIDES | GALSTER, SAMUEL LEONARD | 1693 | §103 | Non-Final OA | — | Pending | Oct 13, 2022 |
| 17620248 | INTERLEUKIN-27 PRODUCING B-CELLS AND USES THEREOF | THUESON, HANNA MARIE | 1638 | §101 | Non-Final OA | — | Pending | Dec 17, 2021 |
| 17602204 | HYBRID NUCLEIC ACID SWITCHES | LIPPOLIS, ALEXANDRA ROSE | 1637 | §103 | Final Rejection | — | Pending | Oct 07, 2021 |
| 17429391 | GENETICALLY MODIFIED HEMATOPOIETIC STEM AND PROGENITOR CELLS (HSPCS) AND MESENCHYMAL CELLS AS A PLATFORM TO REDUCE OR PREVENT METASTASIS, TREAT AUTOIMMUNE AND INFLAMMATORY DISORDERS, AND REBALANCE THE IMMUNE MILIEU AND DYSREGULATED NICHES | ROGERS, ERIC JASON | 1638 | §103 | Final Rejection | 50d overdue | Pending | Aug 09, 2021 |
| 17276959 | BICISTRONIC CHIMERIC ANTIGEN RECEPTORS TARGETING CD19 AND CD20 AND THEIR USES | JUEDES, AMY E | 1644 | §103DP | Final Rejection | 188d overdue | Pending | Mar 17, 2021 |
| 16980205 | ANTI-CD33 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES | EDGINGTONGIORDANO, FRANCESCA | 1643 | §103 | Non-Final OA | — | Pending | Sep 11, 2020 |
| 16650696 | METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A P53 CANCER-SPECIFIC MUTATION | SABILA, MERCY HELLEN | 1654 | §112 | Non-Final OA | 23d | Pending | Mar 25, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial